Please provide your email address to receive an email when new articles are posted on . Properly “dosing” exercise to patients can be a critical part of weight management and keeping patients ...

HealthDay News — Midafternoon dosing with beclomethasone dipropionate is associated with better clinical outcomes in mild-to-moderate atopic asthma, according to a study published online April 15 in ...

Adjunctive use of xanomeline/trospium chloride (Cobenfy) offered no statistically significant benefit over placebo in adults with symptoms of schizophrenia inadequately controlled by an atypical ...

Personalized treatment approaches are crucial for older, frail, and high-risk multiple myeloma patients, focusing on dosing intensity rather than the number of drugs. The MAIA study showed ...

Cobenfy's recent trial failure and underperformance of key assets like Sotyktu and Abecma contribute to a cautious outlook, prompting a rating downgrade to "Hold." Despite debt and market ...

Growth Portfolio revenues reached $5.6 billion, up 16% on a reported basis (18% Ex-FX), primarily driven by Opdivo, Breyanzi, Reblozyl, and Camzyos and reflected the strong early U.S. launch of ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is serving up mixed results for the first three months of the year.

said Yanshan Huang, Ph.D., founder and chief executive officer of Doer Bio. "We're pleased to announce the dosing of first patient in our phase 2 study of DR10624 for the treatment of MASLD/MASH.

It also comes just days after Bristol Myers' recently approved schizophrenia drug, Cobenfy, disappointed in a large clinical trial, leading some Wall Street analysts to substantially lower their ...

The company also noted strong early U.S. launch results for Cobenfy. Conversely, the Legacy Portfolio revenues declined 20% to $5.6 billion, primarily due to generic competition for drugs like ...

Cobenfy Phase 3 Arise results didn’t reach its end point. BMY down 5% after hours. I’m hoping this won’t read through to Puretech given Cobenfy future royalties haven’t factored favourably ...